Astellas Pharma

AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.

Propella Therapeutics is a pharmaceutical company developing innovative lymphatic-targeted oncology therapies. Propella employs medicinal chemistry and lymphatic targeting platform to create oncology drugs starting from known actives that have validated mechanisms of action and biological targets. Lymphatic targeting enables therapies to be delivered directly to targeted tissues via the lymphatic system thereby bypassing first-pass liver effects. The company’s lead drug candidate, PRL-02, is a potential best-in-class CYP17 lyase inhibitor and as such is an androgen receptor (AR) pathway-directed therapy for the treatment of advanced prostate cancer.

Poseida Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company utilizes non-viral gene engineering technologies to create a pipeline of targeted therapies, including both autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates aimed at treating hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency, methylmalonic acidemia, and various genetic liver diseases. Founded in 2014, Poseida is committed to addressing critical health challenges through its focused research and development efforts.

IVERIC bio is a biopharmaceutical company dedicated to discovering and developing innovative treatment options for retinal diseases that have significant unmet medical needs. The company is actively working on therapeutic product candidates aimed at age-related retinal diseases, as well as gene therapy product candidates designed for orphan inherited retinal diseases. Through its focused research and development efforts, IVERIC bio seeks to address critical gaps in the treatment landscape for patients suffering from these conditions.

Taysha Gene Therapies, Inc. is a gene therapy company based in Dallas, Texas, established in 2019, focused on developing adeno-associated virus (AAV)-based gene therapies for monogenic diseases affecting the central nervous system (CNS). The company’s product pipeline includes several therapies currently in development, such as TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha Gene Therapies aims to translate innovative treatments from research to clinical practice efficiently, leveraging a strategic partnership with The University of Texas Southwestern Medical Center to enhance its development and commercialization capabilities. The company's mission is to create curative medicines that target both rare and prevalent CNS conditions, thereby addressing severe and life-threatening diseases.

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 26 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. World-renowned experts from NCCN Member Institutions diagnose and treat patients with a broad spectrum of cancers and are recognized for dealing with complex, aggressive, or rare cancers. NCCN Member Institutions pioneered the concept of the multidisciplinary team approach to patient care and conduct innovative research that contributes significantly to understanding, diagnosing, and treating cancer. NCCN programs offer access to expert physicians, superior treatment, and quality and safety initiatives that continuously improve the effectiveness and efficiency of cancer care.

Iota Biosciences, Inc. is a medical device company based in Berkeley, California, founded in 2017. The company specializes in developing innovative bioelectronic devices that utilize wireless sensors to monitor, measure, and stimulate internal nerves, muscles, and organs for electroceutical applications aimed at treating immune and neural disorders. Iota's technology is built on pioneering ultrasound advancements from the University of California, Berkeley, and includes implantable, mote-sized ultrasonic sensors that facilitate completely wireless neural recordings. This approach eliminates the need for tethered connections, allowing for real-time monitoring and improved treatment of diseases. As a subsidiary of Astellas Pharma Inc., Iota Biosciences is committed to delivering safe and effective diagnostic and therapeutic solutions that transform disease management and significantly enhance patient care.

Nanna Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing drugs for age-related diseases, including mitochondrial, neurodegenerative, cardiovascular/metabolic, joint/tissue diseases, and cancer. Founded in 2012, the company aims to address the unmet medical needs in these areas by targeting fundamental cellular processes to create innovative treatments. Nanna Therapeutics employs a proprietary platform known as the Totally Integrated Medicines Engine (TIME), which utilizes advanced technologies such as microfluidics, nanofabrication, and artificial intelligence to enhance drug discovery. This platform enables the rapid creation and functional screening of millions of novel compounds, thereby accelerating the development of transformative medicines for conditions that currently lack effective therapies. As of April 2020, Nanna Therapeutics operates as a subsidiary of Astellas Pharma Europe Ltd.

Xyphos Biosciences, Inc. is a biotechnology company focused on developing immuno-oncology therapeutics aimed at enhancing the immune system to combat cancer. Founded in 2004 and based in South San Francisco, California, the company specializes in a CAR-T cell therapy platform known as ACCEL (Advanced Cellular Control through Engineered Ligands). This innovative platform allows for precise control over the activity of universal CAR-T cells, referred to as convertibleCAR-T, enabling them to target various tumor-specific antibodies effectively. Xyphos Biosciences provides uniquely modified human receptors that can be selectively controlled using bispecific antibody-like molecules, which enhances the targeting of tumor antigens. This technology aims to improve the potential for durable cancer cures by preventing tumor recurrence through advanced switching and multiplexing capabilities. As of late 2019, Xyphos operates as a subsidiary of Astellas Pharma Inc.

Audentes Therapeutics, a clinical-stage biotechnology company based in San Francisco, is dedicated to developing and commercializing gene therapy products for patients with serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapies, including AT132 and AT342, which are in Phase I/II clinical studies for treating X-linked myotubular myopathy and Crigler-Najjar syndrome, respectively. Additionally, it is exploring treatments for Pompe disease and catecholaminergic polymorphic ventricular tachycardia, along with vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. Audentes has established collaborative agreements for research and development with Genethon and the University of Pennsylvania. Founded in 2012, Audentes Therapeutics became a subsidiary of Astellas US Holding in 2020 and operates as Astellas Gene Therapies, focusing on leveraging its expertise in gene therapy research and commercialization.

LabCentral developing novel cancer treatments: Conkwest, Inc, headquartered in DelMar, California, is opening its research laboratory at LabCentral. Conkwest is an innovative life sciences company that is developing and commercializing cell based treatments for cancer and viral infections.

Iota Biosciences, Inc. is a medical device company based in Berkeley, California, founded in 2017. The company specializes in developing innovative bioelectronic devices that utilize wireless sensors to monitor, measure, and stimulate internal nerves, muscles, and organs for electroceutical applications aimed at treating immune and neural disorders. Iota's technology is built on pioneering ultrasound advancements from the University of California, Berkeley, and includes implantable, mote-sized ultrasonic sensors that facilitate completely wireless neural recordings. This approach eliminates the need for tethered connections, allowing for real-time monitoring and improved treatment of diseases. As a subsidiary of Astellas Pharma Inc., Iota Biosciences is committed to delivering safe and effective diagnostic and therapeutic solutions that transform disease management and significantly enhance patient care.

Potenza Therapeutics, Inc. is a preclinical-stage biotechnology company focused on building a portfolio of oncology programs that utilize the body’s own immune system to seek out, recognize and destroy tumors through a diversity of mechanisms that influence tumor immunity. It was founded in 2014 and headquartered in Cambridge, Massachusetts.

Quethera Limited is a gene therapy company based in Canterbury, United Kingdom, founded in 2013. The company specializes in developing innovative treatments for glaucoma and other ophthalmic diseases, particularly aimed at reducing progressive visual loss associated with these conditions. Quethera collaborates with leading experts in the field of glaucoma to design and conduct clinical trials that evaluate the efficacy and safety of its novel therapies, especially for patients who experience accelerated visual field loss. With a strong foundation in gene therapeutic design and development, Quethera is advancing its research pipeline from preclinical testing into clinical development, striving to enhance treatment options for patients suffering from common blinding eye diseases. As of August 2018, Quethera operates as a subsidiary of Astellas Pharma Inc.

Heartseed Inc., founded in 2015 and located in Tokyo, Japan, focuses on developing myocardial regeneration medicine using induced pluripotent stem (iPS) cells. The company is dedicated to advancing the clinical application of regenerative medicine for heart disease, specifically through the development and commercialization of iPS cell-derived cardiomyocyte replacement therapy aimed at treating advanced heart failure. Heartseed's mission is to transform heart disease treatment by pioneering innovative solutions in myocardial regeneration.

Universal Cells Inc. is a biotechnology company based in Seattle, Washington, founded in 2013. It focuses on developing, licensing, and commercializing stem cell therapies designed to overcome immune rejection, which allows for the creation of universal donor stem cells compatible with all patients. The company utilizes proprietary genome editing technology to engineer stem cells that prevent the expression of polymorphic human leukocyte antigen (HLA) molecules, effectively eliminating the risk of donor tissue rejection. This innovative approach enables the development of off-the-shelf therapeutic products and accelerates the advancement of cell therapies for various diseases and conditions. Universal Cells operates as a subsidiary of Astellas Pharma Inc.

Mitobridge, Inc. is a biotechnology company focused on discovering and developing small molecule therapeutics that enhance mitochondrial function. The company is advancing its clinical compound, MA-0211, an orally bioavailable PPARd modulator designed to address mitochondrial deficits in patients with Duchenne muscular dystrophy. Founded in 2013 and based in Cambridge, Massachusetts, Mitobridge aims to leverage emerging scientific insights linking mitochondrial dysfunction to various diseases. The company's strategy involves establishing proof of concept in rare diseases before expanding into more prevalent conditions. With a strong team of experts in mitochondrial biology, metabolism, and aging, Mitobridge is committed to translating innovative discoveries into effective treatments for genetic, metabolic, and neurodegenerative disorders, as well as age-related diseases. Since its inception, the company has received backing from notable investors, including Astellas Pharma, MPM Capital, and Longwood Fund.

Catalia Health brings together artificial intelligence, psychology, and medicine to deliver lasting change. We create effective patient engagement and generate unique data of value to our customers. Our cloud-based platform delivers unique conversations to patients to help address their ongoing healthcare issues in an effective way. These messages are delivered through mobile apps, a web interface, and our uniquely engaging (and patented) interactive robotic coach.

Ogeda SA is a clinical-stage drug discovery company based in Gosselies, Belgium, that specializes in the invention and development of small molecule drugs targeting G-Protein Coupled Receptors (GPCRs). Founded in 1994 and formerly known as Euroscreen, the company focuses on developing innovative therapies for women's health disorders, with its lead product, fezolinetant, currently in Phase II clinical development. In addition to fezolinetant, Ogeda is advancing other small molecules aimed at treating various endocrine, central nervous system, and inflammatory conditions. The company maintains facilities in Brussels and Paris, and operates as a subsidiary of Astellas Pharma Inc. Through its research, Ogeda seeks to provide effective treatment options for hormone-dependent pathologies and other related health issues.

Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.

Mitobridge, Inc. is a biotechnology company focused on discovering and developing small molecule therapeutics that enhance mitochondrial function. The company is advancing its clinical compound, MA-0211, an orally bioavailable PPARd modulator designed to address mitochondrial deficits in patients with Duchenne muscular dystrophy. Founded in 2013 and based in Cambridge, Massachusetts, Mitobridge aims to leverage emerging scientific insights linking mitochondrial dysfunction to various diseases. The company's strategy involves establishing proof of concept in rare diseases before expanding into more prevalent conditions. With a strong team of experts in mitochondrial biology, metabolism, and aging, Mitobridge is committed to translating innovative discoveries into effective treatments for genetic, metabolic, and neurodegenerative disorders, as well as age-related diseases. Since its inception, the company has received backing from notable investors, including Astellas Pharma, MPM Capital, and Longwood Fund.

Telsar Pharma Inc., a new company that will develop an Astellas drug for a common inflammatory bowel disease.

OSI Pharmaceuticals strives to improve the health and quality of life for patients, develop breakthrough treatment options for physicians, offer rewarding careers to employees, and deliver value to our shareholders. The strategy is to build on the success of our flagship product, Tarceva® (erlotinib), and continue to invest in clinical and pre-clinical drug candidates in oncology, diabetes and obesity to provide longer-term growth. OSI has evolved to become a scientifically strong and financially successful top-tier biopharmaceutical company that is focused on disease areas that impact virtually every family in the world. The Oncology team is dedicated to the discovery and development of molecular targeted therapies to revolutionize the way cancer is treated and improve treatment outcomes. The Diabetes & Obesity team is dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. The strategy for this business team is to advance a pipeline of innovative diabetes and obesity research projects through clinical proof-of-concept studies, with a view to then potentially seeking financially attractive development and commercialization partnerships for these research programs. The goal is to pave the way for the future of oncology, diabetes and obesity treatments. They believe that our Company strategy is poised to deliver a rich pipeline of promising drug candidates that have the potential to significantly improve the treatment options available to patients today.

Agensys a biotechnology company, engages in the research and development of therapeutic human monoclonal antibodies and antibody drug conjugates for the treatment of cancer. It offers products to treat various tumors, as well as prostate, pancreatic, and bladder cancers. The company, formerly known as UroGenesys, was founded in 1997 and is based in Santa Monica, California. As of December 18, 2007, Agensys, Inc. operates as a subsidiary of Astellas Pharma US, Inc.